title: Oral insulin-delivery system for diabetes mellitus.
abstract: Current insulin therapy for diabetes mellitus involves frequent dosing of subcutaneous injections, causing local discomfort, patient noncompliance, hypoglycemia and hyperinsulinemia, among others. While noninvasive therapy through oral delivery is greatly desired, there are challenges that include low bioavailability due to rapid enzymatic degradation in the stomach, inactivation and digestion by proteolytic enzymes in the intestinal lumen, poor permeability across the intestinal epithelium and poor stability. This article reviews patents that provide novel approaches for oral insulin delivery to the bloodstream through the GI tract.
authors.affiliation: Nanobiz LLC & Cocreate Consulting Pvt. Ltd.3322 US Hwy 22 West, Suite 421, Branchburg, NJ 08876, USA.
authors.forename: Minakshi
authors.initials: M
authors.lastname: Kanzarkar
authors.forename: Prem Prakash
authors.initials: PP
authors.lastname: Pathak
authors.forename: Mandar
authors.initials: M
authors.lastname: Vaidya
authors.forename: Charles
authors.initials: C
authors.lastname: Brumlik
authors.forename: Abhishek
authors.initials: A
authors.lastname: Choudhury
mesh_terms: D000284:Administration, Oral; D003920:Diabetes Mellitus / Q000188:drug therapy*; D016503:Drug Delivery Systems; D041981:Gastrointestinal Tract / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D010330:Patents as Topic
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin